I've put together a list of key news and podcast updates by @HCPLiveNews from May 2026 in dermatology.
Check out this list to see what you missed in May!☑️
From new psoriasis and atopic dermatitis data to discussions on health equity, patient engagement, and physician well-being, May was a busy month in dermatology.
Catch up on 7 dermatology headlines you may have missed from May 2026: https://t.co/xOvTXvtw71
#Dermatology
🚨NEW🚨
A supplemental New Drug Application (sNDA) has been submitted by @ArcutisBio to the #FDA to broaden the indication of roflumilast cream 0.05% (Zoryve) for mild to moderate atopic dermatitis in infants down to 3 months of age.
🔗More:
https://t.co/g94VUoejUj
🚨NEW🚨
@US_FDA expands dupilumab (Dupixent) to children aged 2–11 with uncontrolled chronic spontaneous urticaria (CSU)—the first biologic approved for this population in the US.
Read more: https://t.co/UAiqrVFC9r
New on the #SkinofColorSavvy podcast 🎧...
Dr. Vinod Nambudiri of @BrighamWomens, discusses the expanding AAD clinical image collection—addressing gaps in skin tone representation and improving diagnostic accuracy.
🔗 https://t.co/CX4C0A1alW
#Dermatology#AAD2026
Are you caught up on news in #dermatology covered by HCPLive's team in Q1 of 2026?🗒️
If not, this review is for you! Check out our Q1 summary, covering @US_FDA news, new late stage data, and podcast updates.
🔗View here: https://t.co/OSQoZyIDUp
March was anything but quiet in dermatology 👀
Head-to-head trial shakeups, long-term data, and FDA movement all made waves at #AAD2026.
What could this mean for psoriasis & atopic dermatitis care?
Read more: https://t.co/KQ1P8UKppI
AAD 2026 delivered a lot in psoriasis 👀
From next-gen oral TYK2 inhibitors to long-term biologic data and new insights in nail psoriasis + GPP—some key trials could shape where treatment is headed next.
I rounded up 6 you should know:
https://t.co/aQpfz8qhH4
Day 2️⃣ of #AAD2026 coverage is LIVE! 🎙️ We're on the ground in Denver bringing you the latest interviews, data, and insights from the Annual Meeting. Stay tuned — more is coming all day. 👇
https://t.co/Nnm0eOu8NN
Wow, #AAD2026 is busy (as always)!
This conference floor is massive as well.
Check out our updates for @HCPLiveNews's coverage of new dermatology data and interviews with trial investigators: https://t.co/SjICxmRW3y
#HealthNews#SkinHealth
Susan Taylor, MD, founder of @SkinOfColor, opened the SOCS Scientific Symposium with an inspiring call to action for dermatologists and healthcare leaders to stand firm on health equity — even in turbulent times.
#AAD2026#SkinOfColor
🔗 https://t.co/Nnm0eOu8NN
I'm here for @HCPLiveNews covering the 22nd Annual SOCS Scientific Symposium (@SkinOfColor)!
It's a busy meeting, with lots of great talks. So many future leaders in dermatology here!
I have landed and am in Denver for the @AADskin Annual Meeting and the @SkinOfColor Symposium...
It's hotter in Colorado than I anticipated.🌤️
Follow my posts for the next few days for updates at these meetings!
Heading to Denver for #AAD2026 tmmw—if anyone needs me, I'll be the one joining the airport lines with half the dermatology world. ✈️
Kicking off at the @SkinOfColor (SOCS) Scientific Symposium, then covering late-breaking data and interviews for @HCPLiveNews. Stay tuned! 👋
🚨NEW🚨
The @US_FDA has approved icotrokinra for the treatment of psoriasis.
The drug is specifically indicated for adults and pediatric patients aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy.
🔗https://t.co/4Sc41e1z0M
🚨NEW🚨
The @US_FDA has approved secukinumab (COSENTX) for pediatric patients aged 12+ with moderate-to-severe hidradenitis suppurativa (HS), offering a new biologic option in a population with historically limited treatments.
Read more:
https://t.co/VwjCg81Mno
I spoke with Dr. Mark Lebwohl (of @IcahnMountSinai) about his team's new data on an ever-evolving topic in dermatology today...
🔍 Weight loss drugs used in combination with dermatology drugs.
View our new @HCPLiveNews Q&A:
https://t.co/QnAtmEmPcu
#dermatology#HealthNews
I interviewed several leaders in the dermatology field at #MauiDerm2026.🌴
I got a great look at the big developments coming in 2026. Check out my compilation video here... https://t.co/2eKu2MfEeo
🔍What can we expect in dermatology in 2026?
🔍Which new therapies should we be looking out for the most?
This video feature includes several key leaders in the field discussing what they are most looking forward to regarding new data and therapies...
🔗https://t.co/EUltkfC2fK
🚨NEW🚨
Recent phase 3b findings released by @EliLillyandCo suggest combining ixekizumab (Taltz) + tirzepatide (Zepbound) improved skin clearance and weight loss more than ixekizumab alone in #psoriasis patients with obesity/overweight.
More:
https://t.co/DTPSetE18I
RAD 2026 is calling for abstracts that highlight innovation and real-world insights in atopic dermatitis. Share your work with a community dedicated to advancing dermatologic care.
📩 Abstract submissions due May 1, 2026
🔗 Submit here: https://t.co/DxpD30bAJd
I had a great time speaking with all these amazing leaders in the #dermatology field!😎
Check out my coverage of Maui Derm Hawaii here: https://t.co/K4MoWbjN6V
#HealthNews#skinhealth
Aloha from #MauiDerm ☀️🌴
We had a great time connecting with experts, capturing insights, and soaking in the energy at this year’s meeting.
👉 Explore our full #MauiDerm coverage: https://t.co/nKmjLr0QVv